Oxford Biomedica PLC Block listing application (7435R)

TIDMOXB

RNS Number : 7435R

Oxford Biomedica PLC

25 September 2017

Oxford BioMedica

Block listing Application

Oxford, UK - 25 September 2017: Oxford BioMedica plc ("OXB" or "the Group") (LSE: OXB), a leading gene and cell therapy group, announces that applications have been made to the Financial Conduct Authority and the London Stock Exchange for admission to (i) the Premium segment of the Official List and (ii) to trading on the London Stock Exchange for a block listing of 35 million ordinary shares of 1 pence each (the "Ordinary Shares").

The Ordinary Shares are being reserved under a block listing and will be issued from time to time pursuant to the following schemes:

   --      2007 and 2015 Employee Share Option Schemes (15 million Ordinary Shares); and 
   --      Long Term Incentive Plan (20 million Ordinary Shares). 

It is expected that admission of the Ordinary Shares will become effective on 28 September 2017. The Ordinary Shares will rank pari passu in all respects with the Group's existing ordinary shares in issue.

-Ends-

 
  For further information, 
   please contact: 
  Oxford BioMedica plc:                     Tel: [phone] 
   John Dawson, Chief Executive              783 000 
   Officer 
   Stuart Paynter, Chief Financial 
   Officer 
  Financial and corporate communications    Tel: [phone] 
   enquiries:                                5700 
   Consilium Strategic Communications 
   Mary-Jane Elliott/Matthew 
   Neal/Philippa Gardner/Laura 
   Thornton 
 

Notes to editors

About Oxford BioMedica(R)

Oxford BioMedica (LSE:OXB) is a leading gene and cell therapy company focused on developing life changing treatments for serious diseases. Oxford BioMedica and its subsidiaries (the "Group") have built a sector leading lentiviral vector delivery platform (LentiVector(R) ) through which the Group develops in vivo and ex-vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology and CNS disorders. The Group has also entered into a number of partnerships, including with Novartis, Sanofi, GSK, and Immune Design, through which it has long-term economic interests in other potential gene and cell therapy products. Oxford BioMedica is based across several locations in Oxfordshire, UK and employs more than 280 people. Further information is available at www.oxfordbiomedica.co.uk.

This information is provided by RNS

The company news service from the London Stock Exchange

END

ALSZELFLDKFBBBF

(END) Dow Jones Newswires

September 25, 2017 10:05 ET (14:05 GMT)